

Date: 29<sup>th</sup> August, 2022

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza',  
Bandra Kurla Complex, Bandra (E),  
Mumbai - 400 051

Dear Sir/Madam,

**Sub: Successful USFDA RRA at Alembic Pharmaceuticals Bioequivalence Facility  
(Bio-analytical division) at Vadodara**

This is to inform the exchange that the Company has successfully completed the US Food and Drug Administration (USFDA) Remote Regulatory Assessment (RRA) for its Bioequivalence Facility, Bio-analytical division, located at Vadodara, without any observations. The RRA was conducted from 22<sup>nd</sup> August, 2022 to 26<sup>th</sup> August, 2022.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
For Alembic Pharmaceuticals Limited



**Charandeep Singh Saluja**  
Company Secretary

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229  
website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123

Date: 29<sup>th</sup> August, 2022

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

Dear Sir/Madam,

**Sub: Successful USFDA RRA at Alembic Pharmaceuticals Bioequivalence Facility  
(Bio-analytical division) at Vadodara**

This is to inform the exchange that the Company has successfully completed the US Food and Drug Administration (USFDA) Remote Regulatory Assessment (RRA) for its Bioequivalence Facility, Bio-analytical division, located at Vadodara, without any observations. The RRA was conducted from 22<sup>nd</sup> August, 2022 to 26<sup>th</sup> August, 2022.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
For Alembic Pharmaceuticals Limited



**Charandeep Singh Saluja**  
Company Secretary

**ALEMBIC PHARMACEUTICALS LIMITED**